Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Zemplar in Stage IV Pancreatic Cancer Maintenance
NCT03331562Phase 2Completed
- Sponsor
- Translational Genomics Research Institute
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing pembrolizumab & paricalcitol with pembrolizumab & placebo (2 arms). Primary endpoint: Progression-Free Survival at 6 months. Started Dec 2017; status: completed.
02
Drugs
paricalcitol
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03331562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331562.